Description
Delpazolid is an oxazolidinone antibiotic. It is active against a wide range of Gram-positive bacterial clinical isolates, including resistant strains of several species, such as methicillin-resistant
S. aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), and penicillin-resistant
S. pneumoniae (MICs = 0.125-4 μg/ml). Delpazolid increases survival in mouse models of systemic MRSA,
E. faecalis,
S. pneumoniae, and
H. influenzae infection (ED
50s = 2.96, 4.53, 2.28, and 9.96 mg/kg, respectively).
References
[1] Jeong JW, et al. In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Antimicrob Agents Chemother. 2010 Dec;54(12):5359-62. DOI:
10.1128/AAC.00723-10[2] Kim TS, et al. Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus. Antimicrob Agents Chemother. 2017 Aug 24;61(9). DOI:
10.1128/AAC.02752-16